Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.

Author(s): Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R

Affiliation(s): Kala-azar Medical Research Center, Banaras Hindu University, Varanasi, India. shyam_vns@satyam.net.in

Publication date & source: 2002-02, Am J Trop Med Hyg., 66(2):143-6.

Publication type: Clinical Trial; Multicenter Study; Randomized Controlled Trial

In this randomized, double-blind, dose-ranging, multicenter trial, 84 patients with visceral leishmaniasis refractory to antimony therapy were administered liposomal amphotericin B (AmBisome) at cumulative doses of 3.75, 7.5, and 15.0 mg/kg for 5 consecutive days. Posttreatment apparent cure and definite cure were assessed at 2 weeks and 6 months after the end of therapy, respectively. Mild to moderate infusion-related fever and rigors were seen in 29 and 44% of patients, respectively. One patient each in the 3.75- and 7.5-mg groups had detectable parasites on splenic smear at posttreatment evaluation. At 6 months' follow-up, however, 2, 1, and 1 patients relapsed in the 3.75-, 7.5-, and 15.0-mg groups, resulting in definite cure rates of 89, 93, and 97%, respectively. There was no significant difference in the cure rates of the 3 groups. Low-dose liposomal amphotericin B given for 5 days can cure most patients with Indian kala-azar.